- Home
- OPY vs MREO Comparison
OPY vs MREO Comparison
Compare OPY & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPY
- MREO
- Stock Information
- Founded
- OPY 1881
- MREO 2015
- Country
- OPY United States
- MREO United Kingdom
- Employees
- OPY N/A
- MREO N/A
- Industry
- OPY Investment Bankers/Brokers/Service
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- OPY Finance
- MREO Health Care
- Exchange
- OPY Nasdaq
- MREO Nasdaq
- Market Cap
- OPY 619.2M
- MREO 577.6M
- IPO Year
- OPY N/A
- MREO N/A
- Fundamental
- Price
- OPY $61.02
- MREO $3.72
- Analyst Decision
- OPY
- MREO Strong Buy
- Analyst Count
- OPY 0
- MREO 4
- Target Price
- OPY N/A
- MREO $7.50
- AVG Volume (30 Days)
- OPY 33.3K
- MREO 818.6K
- Earning Date
- OPY 10-25-2024
- MREO 11-12-2024
- Dividend Yield
- OPY 1.18%
- MREO N/A
- EPS Growth
- OPY 83.00
- MREO N/A
- EPS
- OPY 6.42
- MREO N/A
- Revenue
- OPY $1,280,442,000.00
- MREO $1,000,000.00
- Revenue This Year
- OPY N/A
- MREO $16.39
- Revenue Next Year
- OPY N/A
- MREO $9.44
- P/E Ratio
- OPY $9.49
- MREO N/A
- Revenue Growth
- OPY 7.32
- MREO N/A
- 52 Week Low
- OPY $36.93
- MREO $1.86
- 52 Week High
- OPY $63.27
- MREO $5.02
- Technical
- Relative Strength Index (RSI)
- OPY 67.21
- MREO 41.37
- Support Level
- OPY $59.03
- MREO $3.18
- Resistance Level
- OPY $60.57
- MREO $4.40
- Average True Range (ATR)
- OPY 1.35
- MREO 0.23
- MACD
- OPY -0.20
- MREO -0.04
- Stochastic Oscillator
- OPY 49.32
- MREO 44.67
About OPY Oppenheimer Holdings Inc. (DE)
Oppenheimer Holdings Inc conducts activities in the securities industry. The company is involved in retail securities brokerage, investment banking (both corporate and public finance), institutional sales and trading, market-making, research, trust services, and investment advisory and asset management services. The company has three segments: private client, asset management, and capital markets. The Private Client segment, commissions and a proportionate amount of fee income earned on assets under management ("AUM"), net interest earnings on client margin loans and cash balances, fees from money market funds, and custodian fees. The company generates the majority of its revenue from the Americas, with the rest from Europe, the Middle East, and Asia.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).